Marvell Launches New Prestera CX Devices; Expands Collaboration with IP Infusion to Deliver on Promise of Software Defined Networking

SANTA CLARA, Calif. and LAS VEGAS, May 7, 2013 /PRNewswire/ -- Marvell (Nasdaq: MRVL) today announced the general availability of new devices within the Prestera^® CX family of packet processors. The new processors feature support for high-density 40GbE/10GbE ports for cloud storage and server interconnect solutions, as well as Ethernet backplanes in modular platforms.

(Photo:  http://photos.prnewswire.com/prnh/20130507/AQ08798)

(Logo:  http://photos.prnewswire.com/prnh/20100719/SF36559LOGO-b)

The Prestera CX device family has been purpose built for highly demanding system architectures, spanning 160G to 1.28T in packet processing capabilities. It offers a line of footprint compatible devices enabling a comprehensive portfolio of products leveraging maximal efficiencies in development efforts. A flexible port mapping scheme allows a variety of physical interconnects, fostering a range of solutions with proprietary ASICs, third-party FPGA, as well as Marvell's Alaska^® PHY devices.

In addition to announcing the availability of the Prestera CX, Marvell also introduced its continued collaboration with IP Infusion. The integrated Marvell Prestera CX8129 and IP Infusion ZebIC solution will enable the next generation of software defined networks, accelerating the seamless delivery of cloud-based services. Supporting capabilities for next-generation IP RAN, base stations and packet transport solutions, the Prestera CX8129 enables timing and synchronization support for applications enabling a new set of services for monetization within the public cloud and carrier and telecommunications infrastructure.

"Marvell is leveraging its robust software defined storage, networking, compute and mobility capabilities to deliver on the promise of enabling platforms and solutions underscoring innovation for next-generation service delivery networks and powering the Connected Lifestyle," said Ramesh Sivakolundu, vice president and general manager, Connectivity, Servers, Infrastructure Business Unit (CSIBU) at Marvell Semiconductor, Inc. "The Prestera CX family continues to drive this vision forward. In building on our collaboration with IP Infusion, we are helping our customers significantly reduce their time to market and increase revenue by providing the most advanced connectivity solutions."

"IP Infusion's software defined networking architecture, with its ability to adapt quickly to new situations and higher workloads, is the ideal approach for networking equipment manufacturers who want to implement a common network software platform across their product lines. When our ZebIC solution is combined with advanced switching chipsets, Marvell and IP Infusion customers have a complete solution with proven technology to come to market quickly," said Kiyoyasu Oishi, CEO and president of IP Infusion. "Today's announcement builds upon our partnership with Marvell to support Marvell's latest switching chipsets and we are excited to continue to our collaboration on future technologies as we move forward together to serve new customers and markets."

The Prestera CX8129 (640G), CX8124 (480G), CX8123 (320G) and the CX8121 (160G) devices are ramping to volume production and in multiple customer designs. A full complement of collateral and System Development Kits (SDK), reference designs (RD) and development boards (DB) are now available. 

Marvell will showcase the Prestera CX products with the ZebIC solution at Interop as part of Marvell's line-up of end-to-end software defined storage, networking, compute and mobility solutions in meeting room Reef F at Mandalay Bay, Las Vegas, May 7-9. 

Related Links:

• Product Information: http://www.marvell.com/switching/prestera-cx/index.jsp
• Marvell Online Press Kit: http://www.marvell.com/company/press_kit/

About IP Infusion

IP Infusion is a leading provider of intelligent network software for enhanced Ethernet and IP services for Mobile Backhaul, Carrier Ethernet, and Data Center networks. Tier one and two OEMs rely on IP Infusion's ZebOS® software and global professional services to bring products to market faster, and to differentiate them from competitors with less cost. Products built on IP Infusion technology are deployed in five 9's reliable networks across five continents, as well as a growing number of enterprises, to improve network performance, decrease network infrastructure costs and grow revenue. IP Infusion is headquartered in Sunnyvale, Calif., and is a wholly owned and independently-operated subsidiary of ACCESS CO., LTD., of Tokyo, Japan. IP Infusion will be exhibiting in booth #1109 at the Mandalay Bay Hotel, May 8-10, 2012. For more information about IP Infusion, please visit www.ipinfusion.com.

About Marvell

Marvell (NASDAQ: MRVL) is a global leader in providing complete silicon solutions enabling the digital connected lifestyle. From mobile communications to storage, cloud infrastructure, digital entertainment and in-home content delivery, Marvell's diverse product portfolio aligns complete platform designs with industry-leading performance, security, reliability and efficiency. At the core of the world's most powerful consumer, network and enterprise systems, Marvell empowers partners and their customers to always stand at the forefront of innovation, performance and mass appeal. By providing people around the world with mobility and ease of access to services adding value to their social, private and work lives, Marvell is committed to enhancing the human experience.

As used in this release, the term "Marvell" refers to Marvell Technology Group Ltd. and its subsidiaries. For more information, please visit www.Marvell.com.

Marvell, Prestera, Alaska and the M logo are registered trademarks of Marvell and/or its affiliates. Other names and brands may be claimed as the property of others.

SOURCE Marvell

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED